Drug intelligence / Profile preview

clindamycin + tretinoin

Development stage
Approved
Lead developer
Valeant Pharmaceuticals
Modality
Hydrogel Systems → Drug Delivery Systems, Small Molecules
Administration
Topical
01

Overview

Clindamycin + tretinoin is a fixed-dose combination topical medication used to treat acne vulgaris, including severe nodular acne, in adults and children over 12 years old. Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of bacterial ribosomes, thereby reducing populations of *Propionibacterium acnes* (now *Cutibacterium acnes*), which are implicated in acne pathogenesis. Tretinoin is a retinoic acid derivative (vitamin A analog) that promotes skin cell turnover, reduces sebum production from oil glands, helps keep pores clear, and stimulates collagen synthesis for improved skin texture. The combination provides enhanced efficacy compared to either agent alone by targeting both inflammatory and non-inflammatory lesions while reducing the risk of antibiotic resistance[1][2][3][4][5].

Brand names
VeltinZiana
Other names
clindamycin and tretinoin topicaltretinoin/clindamycin topical
02

Targets

Bacterial 50S ribosomal subunitRARA (Retinoic acid receptor alpha)

Beyond the preview

Go deeper on clindamycin + tretinoin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on clindamycin + tretinoin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call